Analysts anticipate Agios Pharmaceuticals to report an earnings per share (EPS) of $-1.01.
Anticipation surrounds Agios Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Overview of Past Earnings
Last quarter the company missed EPS by $0.10, which was followed by a 1.21% drop in the share price the next day.
Here's a look at Agios Pharmaceuticals's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
-1.59
-1.65
-1.65
-1.70
EPS Actual
-1.69
-1.45
-1.72
-1.64
Price Change %
-1.0%
-0.0%
-1.0%
7.000000000000001%
Analysts' Perspectives on Agios Pharmaceuticals
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Agios Pharmaceuticals.
Analysts have given Agios Pharmaceuticals a total of 5 ratings, with the consensus rating being Outperform. The average one-year price target is $53.6, indicating a potential 14.46% upside.
Analyzing Ratings Among Peers
The following analysis focuses on the analyst ratings and average 1-year price targets of Veracyte, Catalyst Pharmaceuticals and Geron, three prominent industry players, providing insights ...